Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma (Q38312053)

2 September 2017

1 reference

title

Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma (English)

1 reference

2 September 2017

1 reference

Peter Hersey

1

1 reference

PubMed ID

25572788

2 September 2017

Kavitha Gowrishankar

series ordinal

2

1 reference

PubMed ID

25572788

2 September 2017

language of work or name

English

0 references

publication date

1 January 2015

1 reference

2 September 2017

1 reference

2 September 2017

11

1 reference

2 September 2017

1

1 reference

2 September 2017

133-140

1 reference

Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I)

2 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Surgical management of distant metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Chemotherapy for metastatic melanoma: time for a change?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Which drug, and when, for patients with BRAF-mutant melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Review and cross-validation of gene expression signatures and melanoma prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Innate and adaptive immune cells in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

BRAF-targeted therapy and immune responses to melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

The anticancer effects of HDAC inhibitors require the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.205

21 January 2018

Identifiers

DOI

10.2217/FON.14.205

1 reference

2 September 2017

1 reference

PubMed ID

25572788